Parkside Financial Bank & Trust’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $117K | Buy |
2,436
+283
| +13% | +$12.2K | 0.01% | 683 |
|
|
2026
Q1 | $79.1K | Sell |
2,153
-149
| -6% | -$7.06K | 0.01% | 784 |
|
|
2025
Q4 | $117K | Sell |
2,302
-1,103
| -32% | -$56.4K | 0.01% | 635 |
|
|
2025
Q3 | $189K | Buy |
3,405
+538
| +19% | +$31.5K | 0.01% | 458 |
|
|
2025
Q2 | $198K | Buy |
2,867
+571
| +25% | +$38.8K | 0.02% | 430 |
|
|
2025
Q1 | $159K | Buy |
2,296
+245
| +12% | +$20.2K | 0.02% | 436 |
|
|
2024
Q4 | $176K | Buy |
2,051
+114
| +6% | +$12.3K | 0.02% | 404 |
|
|
2024
Q3 | $231K | Buy |
1,937
+143
| +8% | +$19.1K | 0.03% | 342 |
|
|
2024
Q2 | $256K | Sell |
1,794
-574
| -24% | -$76.1K | 0.04% | 302 |
|
|
2024
Q1 | $304K | Buy |
2,368
+427
| +22% | +$50.8K | 0.05% | 275 |
|
|
2023
Q4 | $201K | Buy |
1,941
+435
| +29% | +$43K | 0.04% | 307 |
|
|
2023
Q3 | $137K | Sell |
1,506
-110
| -7% | -$9.69K | 0.03% | 332 |
|
|
2023
Q2 | $131K | Buy |
1,616
+900
| +126% | +$73.5K | 0.03% | 347 |
|
|
2023
Q1 | $57K | Hold |
716
| – | – | 0.02% | 539 |
|
|
2022
Q4 | $48.5K | Buy |
716
+42
| +6% | +$2.46K | 0.01% | 582 |
|
|
2022
Q3 | $34K | Hold |
674
| – | – | 0.01% | 620 |
|
|
2022
Q2 | $38K | Hold |
674
| – | – | 0.01% | 611 |
|
|
2022
Q1 | $37K | Sell |
674
-94
| -12% | -$4.82K | 0.01% | 636 |
|
|
2021
Q4 | $43K | Buy |
768
+94
| +14% | +$5.09K | 0.01% | 560 |
|
|
2021
Q3 | $32K | Hold |
674
| – | – | 0.01% | 632 |
|
|
2021
Q2 | $28K | Hold |
674
| – | – | 0.01% | 676 |
|
|
2021
Q1 | $23K | Hold |
674
| – | – | 0.01% | 728 |
|
|
2020
Q4 | $24K | Hold |
674
| – | – | 0.01% | 668 |
|
|
2020
Q3 | $23K | Hold |
674
| – | – | 0.01% | 605 |
|
|
2020
Q2 | $22K | Hold |
674
| – | – | 0.01% | 618 |
|
|
2020
Q1 | $20K | Hold |
674
| – | – | 0.01% | 570 |
|
|
2019
Q4 | $20K | Hold |
674
| – | – | 0.01% | 651 |
|
|
2019
Q3 | $17K | Hold |
674
| – | – | 0.01% | 669 |
|
|
2019
Q2 | $17K | Hold |
674
| – | – | 0.01% | 688 |
|
|
2019
Q1 | $18K | Hold |
674
| – | – | 0.01% | 641 |
|
|
2018
Q4 | $16K | Hold |
674
| – | – | 0.01% | 629 |
|
|
2018
Q3 | $16K | Hold |
674
| – | – | 0.01% | 667 |
|
|
2018
Q2 | $16K | Hold |
674
| – | – | 0.01% | 643 |
|
|
2018
Q1 | $17K | Hold |
674
| – | – | 0.01% | 606 |
|
|
2017
Q4 | $18K | Hold |
674
| – | – | 0.01% | 604 |
|
|
2017
Q3 | $16K | Hold |
674
| – | – | 0.01% | 620 |
|
|
2017
Q2 | $14K | Hold |
674
| – | – | 0.01% | 645 |
|
|
2017
Q1 | $12K | Hold |
674
| – | – | 0.01% | 653 |
|
|
2016
Q4 | $12K | Hold |
674
| – | – | 0.01% | 656 |
|
|
2016
Q3 | $14K | Sell |
674
-174
| -21% | -$4.31K | 0.01% | 643 |
|
|
2016
Q2 | $23K | Hold |
848
| – | – | 0.01% | 519 |
|
|
2016
Q1 | $23K | Hold |
848
| – | – | 0.01% | 491 |
|
|
2015
Q4 | $25K | Sell |
848
-38
| -4% | -$1.05K | 0.01% | 469 |
|
|
2015
Q3 | $24K | Buy |
+886
| New | +$25.1K | 0.01% | 447 |
|
Other funds holding NVO
F
Parkside Financial Bank & Trust's NVO Position: Q2 2026 in Review
Parkside Financial Bank & Trust increased its Novo Nordisk (NVO) stake by 13% in Q2 2026, buying an estimated $12.2K and bringing the position to 2,436 shares worth $117K. The position accounts for 0.01% of the portfolio, ranked #683.
Parkside Financial Bank & Trust first reported a position in NVO in Q3 2015 and has held it in 44 quarters since. The position peaked at $304K in Q1 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Parkside Financial Bank & Trust held 2,436 shares of Novo Nordisk worth $117K as of Q2 2026.
- Parkside Financial Bank & Trust bought 283 Novo Nordisk shares in Q2 2026, an estimated $12.2K.
- Novo Nordisk made up 0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #683 holding.
- Parkside Financial Bank & Trust first reported a position in Novo Nordisk in Q3 2015 and has held it in 44 quarters since.
- Parkside Financial Bank & Trust's Novo Nordisk position peaked at $304K in Q1 2024.
- 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.